



(86) **Date de dépôt PCT/PCT Filing Date:** 2012/11/02
(87) **Date publication PCT/PCT Publication Date:** 2014/04/17
(45) **Date de délivrance/Issue Date:** 2017/02/21
(85) **Entrée phase nationale/National Entry:** 2015/04/07
(86) **N° demande PCT/PCT Application No.:** CN 2012/083977
(87) **N° publication PCT/PCT Publication No.:** 2014/056270
(30) **Priorité/Priority:** 2012/10/08 (CN201210394006.2)



(51) **Cl.Int./Int.Cl. C07H 19/073** (2006.01),
A61K 41/00 (2006.01), **C07D 487/22** (2006.01)

(72) **Inventeurs/Inventors:**
PANDEY, RAVINDRA K., US;
CHEN, YIHUI, US;
BAI, HUA, CN;
CHEN, ZHENLIANG, CN

(73) **Propriétaire/Owner:**
ZHEJIANG HISUN PHARMACEUTICAL CO. LTD., CN

(74) **Agent:** OYEN WIGGS GREEN & MUTALA LLP

(54) **Titre : PHOTSENSIBILISANT CIBLANT UNE THYMIDINE KINASE ET COMPOSITION PHARMACEUTIQUE ET UTILISATION POUR LE TRAITEMENT DU CANCER ASSOCIE**
(54) **Title: TARGETING THYMIDINE KINASE PHOTSENSITIZER AND PHARMACEUTICAL COMPOSITION AND USE FOR CANCER TREATMENT THEREOF**



(57) **Abrégé/Abstract:**

The present invention relates to the field of medicine, and discloses a targeting thymidine kinase photosensitizer and a pharmaceutical composition and use for cancer treatment thereof. The targeting thymidine kinase photosensitizer disclosed by the



(57) Abrégé(suite)/Abstract(continued):

present invention improves the selectivity of photosensitizers to tumour cells and has better tolerance and can reach maximum blood concentration in 24 hours. The targeting thymidine kinase photosensitizer disclosed by the present invention has a bigger conjugated system, a longer absorption wavelength and an advantage in treating depth tumours; the wavelength area does not need to consume much energy of a light-output device and even LEDs can be used, which render PDT more practical and economical. The targeting thymidine kinase photosensitizer disclosed by the present invention can be used not only for diagnosis, but also for treating prostatic carcinoma via the guidance of fluorescence imaging. The pharmaceutical composition disclosed by the present invention uses a combination of a chemotherapeutic agent and the targeting thymidine kinase photosensitizer, which further improves the therapeutic effect of the PDT method, expands the application range for tumours and has good effects on metastatic tumours as well. (see above formula)

